Medical Oncology Department, Aga Khan University Hospital, Karachi, Pakistan.
Internal Medicine Department, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Pathol Res Pract. 2023 May;245:154455. doi: 10.1016/j.prp.2023.154455. Epub 2023 Apr 7.
Lung cancer is one of the most common solid malignancies. Tissue biopsy is the standard method for accurately diagnosing lung and many other malignancies over decades. However, molecular profiling of tumors leads to establishing a new horizon in the field of precision medicine, which has now entered the mainstream in clinical practice. In this context, a minimally invasive complementary method has been proposed as a liquid biopsy (LB) which is a blood-based test that is gaining popularity as it provides the opportunity to test genotypes in a unique, less invasive manner. Circulating tumor cells (CTC) captivating the Circulating-tumor DNA (Ct-DNA) are often present in the blood of lung cancer patients and are the fundamental concept behind LB. There are multiple clinical uses of Ct-DNA, including its role in prognostic and therapeutic purposes. The treatment of lung cancer has drastically evolved over time. Therefore, this review article mainly focuses on the current literature on circulating tumor DNA and its clinical implications and future goals in non-small cell lung cancer.
肺癌是最常见的实体恶性肿瘤之一。数十年来，组织活检一直是准确诊断肺癌和许多其他恶性肿瘤的标准方法。然而，肿瘤的分子分析为精准医学领域开辟了新的视野，目前已在临床实践中占据主流地位。在此背景下，提出了一种微创的补充方法，即液体活检（LB），这是一种基于血液的检测方法，由于其提供了以独特、微创的方式检测基因型的机会，因此越来越受欢迎。在肺癌患者的血液中经常存在循环肿瘤细胞（CTC）和循环肿瘤 DNA（Ct-DNA），这是 LB 的基本概念。Ct-DNA 有多种临床用途，包括在预后和治疗目的中的作用。随着时间的推移，肺癌的治疗已经发生了巨大的变化。因此，本文主要侧重于关于循环肿瘤 DNA 的当前文献及其在非小细胞肺癌中的临床意义和未来目标。
